- Home
- KNRX vs CTXR Comparison
KNRX vs CTXR Comparison
Compare KNRX & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KNRX | CTXR |
|---|---|---|
| Founded | 2009 | 2007 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.7M | 18.9M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | KNRX | CTXR |
|---|---|---|
| Price | $0.45 | $0.57 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 73.4K | ★ 393.7K |
| Earning Date | 06-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.38 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $147.57 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.39 | $0.48 |
| 52 Week High | $3.45 | $2.24 |
Technical Indicators
Market Signals| Indicator | KNRX | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 31.41 | 40.40 |
| Support Level | $0.39 | $0.48 |
| Resistance Level | $0.67 | $0.74 |
| Average True Range (ATR) | 0.08 | 0.04 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 26.49 | 10.95 |
Price Performance
Historical ComparisonAbout KNRX KNOREX LTD. Class A Ordinary Shares
Knorex Ltd is a B2B technology company providing programmatic advertising products and solutions to marketers to streamline and automate their advertising and marketing workflows. The company's product, Knorex XPOSM, is a self-service enterprise-grade cloud platform with a suite of advertising management and execution (AMX) applications.
About CTXR Citius Pharmaceuticals Inc.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.